Home / Stocks / ZVRA

Zevra Therapeutics (ZVRA, Pharmaceuticals) Stock Valuation & Fair Value High quality, attractively priced for its growth

Zevra Therapeutics (ZVRA, Pharmaceuticals) trades at a blended P/E of 10.0, about 50% above its historical normal valuation, with a forward growth estimate of 10.8% and a PEG of 0.92. Analysts' one-year estimates have been hit 10% of the time. Priced at its historical normal P/E of 6.6 on the same blended earnings, the 2026-09-18 close of $11.61 corresponds to about $7.73 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
10.0
Normal P/E
6.6
PEG
0.92
Fwd growth
10.8%
Div yield
0.0%
RSI (14)
41.8
Neutral
Technical context
  • Price $11.32 at the 2026-09-23 close, 5.3% below the 20-day average ($11.95) and 2.3% below the 50-day ($11.59).
  • RSI (14) at 41.8.
  • 52-week range $8.10 to $14.75: the price is 23.3% below the high and 39.8% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ZVRA is $25.00 across 9 analysts, 120.8% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: high quality, attractively priced for its growth. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to high quality, attractively priced for its growth (2026-09-21).

Blended P/E and rating by weekBlended P/E moved from 8.4 to 10.0 between 2026-07-31 and 2026-09-21, against a normal P/E of 6.6, with 1 rating change over 18 recorded weeks.2026-07-31: P/E 8.4, Quality business with a solid forward outlook (recalculated)2026-08-03: P/E 8.3, Quality business with a solid forward outlook2026-08-07: P/E 8.3, Quality business with a solid forward outlook (recalculated)2026-08-10: P/E 9.7, High quality, attractively priced for its growth2026-08-14: P/E 9.7, High quality, attractively priced for its growth (recalculated)2026-08-17: P/E 9.5, High quality, attractively priced for its growth2026-08-21: P/E 9.5, High quality, attractively priced for its growth (recalculated)2026-08-24: P/E 10.0, High quality, attractively priced for its growth2026-08-27: P/E 10.0, High quality, attractively priced for its growth (recalculated)2026-08-28: P/E 10.0, High quality, attractively priced for its growth (recalculated)2026-08-30: P/E 10.0, High quality, attractively priced for its growth (recalculated)2026-08-31: P/E 9.8, High quality, attractively priced for its growth2026-09-05: P/E 9.8, High quality, attractively priced for its growth (recalculated)2026-09-07: P/E 10.6, High quality, attractively priced for its growth2026-09-12: P/E 10.6, High quality, attractively priced for its growth (recalculated)2026-09-14: P/E 10.3, High quality, attractively priced for its growth2026-09-19: P/E 10.3, High quality, attractively priced for its growth (recalculated)2026-09-21: P/E 10.0, High quality, attractively priced for its growth7.08.09.010.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 6.6
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 8.4+27%Quality business with a solid forward outlook
2026-08-03P/E 8.3+25%Quality business with a solid forward outlook
2026-08-10P/E 9.7+46%High quality, attractively priced for its growth
2026-09-07P/E 10.6+59%High quality, attractively priced for its growth
2026-09-21P/E 10.0+50%High quality, attractively priced for its growth ← now

Frequently asked questions

Is Zevra Therapeutics stock overvalued?

At a blended P/E of 10.0 versus its historical normal P/E of 6.6, Zevra Therapeutics trades about 50% above its typical valuation, with a PEG of 0.92 on 10.8% forward growth. tickerseer currently rates it high quality, attractively priced for its growth.

What is Zevra Therapeutics's fair value and PEG?

Zevra Therapeutics trades at a blended P/E of 10.0 against a historical normal P/E of 6.6, a PEG of 0.92, and a forward growth estimate of 10.8%. Priced at its historical normal P/E of 6.6 on the same blended earnings, the 2026-09-18 close of $11.61 corresponds to about $7.73 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Zevra Therapeutics changed?

tickerseer's rating moved from quality business with a solid forward outlook (2026-07-31) to high quality, attractively priced for its growth (2026-09-21).

What is the analyst price target for Zevra Therapeutics?

The mean Wall Street price target for Zevra Therapeutics is $25.00 across 9 analysts, 120.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ZVRA free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.